CLINICAL_TRIALS
trial_result
· 2012-05-02
Clinical Trial Update: Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients [Phase 1]
Summary
Phase 1 pharmacokinetic study of LAF237 and its metabolites in patients with mild renal impairment who have type 2 diabetes mellitus.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis | Conditions: Type 2 Diabetes Mellitus | Phase 1 | Status: COMPLETED